A Centennial Letdown for FDA's Biologics Group

Publisher Website
Google Scholar
Abstract
New leaders at the Food and Drug Administration are pushing a big shakeup of the division that oversees biologics in a way that seems to de-emphasize research, although they cite other reasons for making changes. However, many researchers at the Center for Biologics Evaluation and Research and outside scientists have begun arguing that the real purpose of the move is to strip away CBER's special status as a regulator that also supports substantial intramural research.

This publication has 0 references indexed in Scilit: